TS-Signaling Coordination in Cancer-990x120-1

Event Overview

Since its discovery by Arnold Levine in 1979, the tumor protein p53 has transformed the field of cancer research. p53 signaling plays a key role in regulating the cell cycle, maintaining genome stability, and preventing mutations caused by stress or DNA damage. In fact, more than 50% of human cancers have a mutation in the p53 gene. Today, scientists are continuing to make new discoveries regarding p53 signaling and its role in cancer.

In this webinar brought to you by The Scientist and sponsored by IsoPlexis, Arnold Levine from the Institute for Advanced Study will discuss his groundbreaking discovery of p53 and the evolution of the field since then. Jon Chen from IsoPlexis will discuss the use of single-cell phosphoproteomics in identifying changes in key signaling networks including p53, and how signaling alterations can affect treatment resistance in glioblastoma.

Topics to be covered
  • The foundational discovery of p53 and its recent advances
  • How changes in MDM2-p53 signaling affects the timing and development of tumors
  • The effect of signaling networks on cancer therapy resistance
  • Using single-cell phosphoproteomics to identify key signaling events in glioblastoma
  • Altering signaling coordination to mitigate adaptive resistance
Tuesday, June 30, 2020
2:30 - 4:00 PM, Eastern Standard Time


Arnold Levine, PhD
Professor Emeritus
Simons Center for Systems Biology
Institute for Advanced Study

Jon Chen
Technology Co-Inventor


Register Now

The Structure and Functions of the p53 Pathway: Information Acquisition, Redundancy, and Connectivity

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.